Evidence map›Paper›PMID 30842628›Full record

ReviewCellular & molecular immunology2019

Composite tissue allotransplantation: opportunities and challenges.

Jasper Iske, Yeqi Nian, Ryoichi Maenosono, Max Maurer, Igor M Sauer, Stefan G Tullius

Abstract readReview
In one paragraph

Review in Cellular & molecular immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Chronic Rejection in Facial Vascularized Composite Allotransplantation (fVCA).Results and problems in cell differentiation · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jasper IskeDivision of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yeqi NianDivision of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ryoichi MaenosonoDivision of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Max MaurerDepartment of Surgery, Charité - Universitätsmedizin Berlin, Campus Charité Mitte and Virchow-Klinikum, Berlin, Germany.
Igor M SauerDepartment of Surgery, Charité - Universitätsmedizin Berlin, Campus Charité Mitte and Virchow-Klinikum, Berlin, Germany.
Stefan G TulliusDivision of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. stullius@bwh.harvard.edu.

Funding

Consequences of Aging on Immune Response and Transplant OutcomeR01AG039449 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI TULLIUS, STEFAN GUNTHER · 2012 to 2016
$1.6M
Consequences of Aging on Immune Response and Transplant OutcomeR56AG039449 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI TULLIUS, STEFAN GUNTHER · 2018 to 2018
$643k
NIA NIH HHS R01 AG039449NIA NIH HHS R56 AG039449
6 · The paper itself

Abstract

Vascularized composite allotransplants (VCAs) have unique properties because of diverse tissue components transplanted en mass as a single unit. In addition to surgery, this type of transplant also faces enormous immunological challenges that demand a detailed analysis of all aspects of alloimmune responses, organ preservation, and injury, as well as the immunogenicity of various tissues within the VCA grafts to further improve graft and patient outcomes. Moreover, the side effects of long-term immunosuppression for VCA patients need to be carefully balanced with the potential benefit of a non-life-saving procedure. In this review article, we provide a comprehensive update on limb and face transplantation, with a specific emphasis on the alloimmune responses to VCA, established and novel immunosuppressive treatments, and patient outcomes.

Indexed as

Adaptive ImmunityGraft RejectionGraft SurvivalHumansImmune ToleranceImmunity, InnateImmunosuppression TherapyImmunosuppressive AgentsRisk FactorsSkinSkin TransplantationVascularized Composite AllotransplantationImmunosuppressive Agents

Identifiers

PMID30842628
PMCPMC6462029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.